No Detail Found!

Evaluating long-term antibody responses to booster doses of COVID-19 vaccines in the Pakistani population

Author(s)
Shakir Hussain Molecular Biology Section, Pathology Department, Indus Hospital & Health Network, Karachi 75190, Pakistan.
Fouzia Naseer Molecular Biology Section, Pathology Department, Indus Hospital & Health Network, Karachi 75190, Pakistan.
Fatima Kanani Chemical Pathology Section, Pathology Department, Indus Hospital & Health Network, Karachi 75190, Pakistan.
Javeria Aijaz Molecular Biology Section, Pathology Department, Indus Hospital & Health Network, Karachi 75190, Pakistan.
Abstract
Background & Objective: Nearly 80 million of the Pakistani population received two doses of the BBIBP-CorV vaccine, against SARS-CoV-2, and 2.6 million people received heterologous booster doses up to February 2022. Our objective was to measure the long-term change of antibody titers in persons vaccinated with Pfizer-BioNTech COVID-19 following two doses of BBIBP-CorV. Methods: Serum specimens from forty-three participants were collected 4-8 weeks following two doses of BBIBPCorV at the Indus Hospital & Health Network, Karachi. A second set of serum specimens were collected 2-12 months after Pfizer-BioNTech COVID-19 booster dose administration. Chemiluminescent Microparticle Immunoassay (CMIA, Abbott Alinity Quant), and the pseudotyped lentivirus antibody neutralization assay were performed on all specimens. The latter assay was reported as log half-maximal inhibitory concentrations (IC50), calculated using a nonlinear regression algorithm (log [inhibitor] versus normalized response variable slope) in Graph Pad Prism 9. Paired sample t-test was used to ascertain the statistical significance of the diference in means of antibody titers obtained before and after the booster vaccine doses. Results: Mean log10 values obtained with CMIA before and after the booster dose were 2.90 AU/mL and 3.87 AU/mL respectively, while the corresponding log10 IC50 values obtained through pseudotyped lentivirus antibody neutralization assay were 2.45 and 2.80. These diferences were statistically significant with CMIA (p = <0.00001), but not with pseudotyped lentivirus antibody neutralization assay (p = 0.06318.). Conclusion: A heterologous booster dose with Pfizer-BioNTech COVID-19 vaccine following two doses of BBIBP results in increased total antibody titers, though neutralizing antibody titers may start to wane a few months after the booster dose.
Publication Details
Page(s) 528-534
Published Journal: Pakistan Journal of Medical Sciences, Volume: 40, Issue: 2, Year: 2024

Request the full text from PASTIC

Keywords
COVID-19, Pakistan, vaccine, Covid-19, Immunoassay, BBIBP-CorV, CMIA, pseudotyped, BNT162b2 mRNA
0

Citations

0

Downloads

83

Views